Lateonset Pompe Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for lateonset pompe disease. 10 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
10
Active US patents
72/100
Avg vulnerability
—
Annual revenue covered

Originators in Lateonset Pompe Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 10 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating lateonset pompe disease. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
33
3
35
2
36
1
37
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zavesca
MIGLUSTAT
 AstraZeneca 10 72 — 2033-03-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12419937 Zavesca method of use 75 2033-03-07
12414985 Zavesca method of use 75 2036-12-29
12246062 Zavesca method of use 75 2038-09-16
11278599 Zavesca method of use 70 2033-03-07
10512677 Zavesca method of use 70 2033-03-07
10208299 Zavesca method of use 70 2035-09-30
11753632 Zavesca method of use 70 2035-09-30
10961522 Zavesca method of use 70 2035-09-30
11278601 Zavesca method of use 70 2036-12-29
10857212 Zavesca method of use 70 2037-08-12

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10857212 Zavesca method of use 70 2037-08-12
11278601 Zavesca method of use 70 2036-12-29
10208299 Zavesca method of use 70 2035-09-30
10961522 Zavesca method of use 70 2035-09-30
11753632 Zavesca method of use 70 2035-09-30
10512677 Zavesca method of use 70 2033-03-07
11278599 Zavesca method of use 70 2033-03-07
12246062 Zavesca method of use 75 2038-09-16
12414985 Zavesca method of use 75 2036-12-29
12419937 Zavesca method of use 75 2033-03-07

Related